ADRIAMYCIN-CYCLOPHOSPHAMIDE AND ADRIAMYCIN-CIS-DICHLORODIAMMINEPLATINUM(II) COMBINATION CHEMOTHERAPY IN PATIENTS WITH ADVANCED CANCER

Google Scholar
  • 1 January 1977
    • journal article
    • research article
    • Vol. 61  (5) , 869-873
Abstract
Patients with a wide variety of previously treated, advanced solid tumors were assigned to receive adriamycin-cis-dichlorodiammineplatinum(II) (cis-Pt) or adriamycin-cyclophosphamide as combination chemotherapy. Hematologic toxicity was prominent but short-lived in most patients. Renal toxicity occurred in 14 of 23 patients receiving cis-Pt and frequently precluded further administration of that agent. Of the patients receiving adriamycin-cis-Pt, 37.5% had useful responses, with 4 of 6 patients with bronchogenic carcinomas showing partial regression of disease and 2 patients with embryonal cell carcinoma of the testes showing complete responses. In the patients receiving adriamycin-cyclophosphamide, 1 complete response occurred in a patient with a malignant lymphoma, and the overall response rate was 18%. The combination of adriamycin-cis-Pt merits further study, especially in bronchogenic carcinoma.

This publication has 2 references indexed in Scilit: